STAT

In rare move, FDA reverses course on drug developed by CEO with ties to Trump

In a rare reversal, the FDA has given Amicus Therapeutics the OK to submit its drug for approval, withdrawing a request that it do another clinical trial.

The Food and Drug Administration has changed its tune on an experimental drug for a deadly rare disease, withdrawing a request that the company developing it run another clinical trial. The unusual move comes after President Trump met with the company’s CEO — and promised to speed up what he called a “slow and burdensome” process for drug approvals.

Amicus Therapeutics, a New Jersey biotech company, announced on Tuesday morning that the

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readScience
Amid Privacy Concerns, Startup Becomes First Consumer DNA Company To Offer Anonymous Sequencing
Nebula will offer anonymous testing amid public concerns about the privacy of genetic data and law enforcement use of public DNA databases to identify suspects.
STAT3 min readPolitics
Pelosi’s Drug Pricing Plan Would Let Medicare Negotiate Prices For Up To 250 Drugs
The new legislation is more aggressive than prior concepts that had circulated among lobbyists and congressional staff this year.
STAT5 min read
‘Please Know You’re Not Alone’: For Dementia Caregivers, A Place To Share With Strangers — And Be Honest
It was an indescribable relief to finally connect with someone who understood what, exactly, it was like.